Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,560 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-small Cell Lung Cancer (NSCLC) Clear all
Terminated Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

NCT00003492
View directory record Official record
Conditions
Stage IV Lung Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 15, 2026, 8:50 AM EDT
Completed No phase listed Observational

BESPOKE Study of ctDNA Guided Immunotherapy

NCT04761783
View directory record Official record
Conditions
Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 15, 2026, 8:50 AM EDT
Active, not recruiting No phase listed Observational

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

NCT04994795
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
Predictive models (data collection)
Other
Lead sponsor
Sophia Genetics SAS
Industry
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Iowa City, Iowa • Worcester, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 15, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00960999
View directory record Official record
Conditions
Lung Cancer
Interventions
Single-fraction stereotactic body radiation therapy (SBRT), Multiple-fraction stereotactic body radiation therapy (SBRT)
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
35
States / cities
Auburn, California • Berkeley, California • Cameron Park, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 15, 2026, 8:50 AM EDT
Terminated Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

NCT06870487
View directory record Official record
Conditions
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
Interventions
PF-08046032, Sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 15, 2026, 8:50 AM EDT
Terminated Phase 1 Interventional

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

NCT03418532
View directory record Official record
Conditions
EGFR-mutated NSCLC (Disorder)
Interventions
MP0250 DARPin® drug candidate, Osimertinib
Combination Product
Lead sponsor
Molecular Partners AG
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Scottsdale, Arizona • Duarte, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 15, 2026, 8:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099
View directory record Official record
Conditions
NSCLC
Interventions
REGN5093
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Orange, California • Washington D.C., District of Columbia • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 8:50 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

NCT03861793
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ALKS 4230, Pembrolizumab
Biological
Lead sponsor
Mural Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
17
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 15, 2026, 8:50 AM EDT
Active, not recruiting Phase 3 Interventional

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970
View directory record Official record
Conditions
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Interventions
Patritumab Deruxtecan, Platinum-based chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Anchorage, Alaska • Springdale, Arkansas • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 15, 2026, 8:50 AM EDT
Completed Phase 2 Interventional

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00118183
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
docetaxel, cetuximab, bortezomib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 15, 2026, 8:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

NCT04074967
View directory record Official record
Conditions
Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab, Phase II ARRY-614 + nivolumab+ipilimumab (melanoma), Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 15, 2026, 8:50 AM EDT
Not listed Phase 1Phase 2 Interventional

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

NCT00516100
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
bortezomib
Drug
Lead sponsor
Aptium Oncology Research Network
Network
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 15, 2026, 8:50 AM EDT
Completed Phase 1 Interventional

Intraoperative Imaging of Pulmonary Nodules by SGM-101

NCT04315467
View directory record Official record
Conditions
Lung Cancer, Lung Nodule, Non Small Cell Lung Cancer
Interventions
SGM-101, Near infrared camera imaging system
Drug · Device
Lead sponsor
Sunil Singhal
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 15, 2026, 8:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

NCT05091528
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
Interventions
SBT6050, trastuzumab deruxtecan, tucatinib, trastuzumab, capecitabine
Drug
Lead sponsor
Silverback Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 15, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT02998528
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Nivolumab, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
57
States / cities
Glendale, Arizona • Los Angeles, California • Denver, Colorado + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 15, 2026, 8:50 AM EDT
Terminated Not applicable Interventional

Daily vs. Non-Daily SBRT for NSCLC

NCT03624907
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Daily Stereotactic Body Radiotherapy, Non-Daily Stereotactic Body Radiotherapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 15, 2026, 8:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Interventions
Divarasib, Sotorasib, Adagrasib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 8:50 AM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00128622
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 15, 2026, 8:50 AM EDT
Completed Phase 1 Interventional

Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer

NCT00322751
View directory record Official record
Conditions
Lung Cancer
Interventions
Topotecan
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 15, 2026, 8:50 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00019929
View directory record Official record
Conditions
Lung Cancer
Interventions
mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 15, 2026, 8:50 AM EDT
Terminated Phase 2 Interventional

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

NCT05715229
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 15, 2026, 8:50 AM EDT
Terminated Early Phase 1 Interventional

Amatuximab for High Mesothelin Cancers

NCT01413451
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Mesothelioma, Ovarian Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Amatuximab (MORab-009)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 15, 2026, 8:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

NCT05651022
View directory record Official record
Conditions
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
Interventions
Decoy20, Tislelizumab
Drug
Lead sponsor
Indaptus Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 15, 2026, 8:50 AM EDT
Terminated Phase 1 Interventional

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

NCT07121829
View directory record Official record
Conditions
Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
Interventions
Tovorafenib, Tovorafenib Drug: Pimasertib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 15, 2026, 8:50 AM EDT